Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:GNCA
- CUSIP: N/A
- Web: www.genocea.com
Capitalization:- Market Cap: $141.1 million
- Outstanding Shares: 28,502,000
Average Prices:- 50 Day Moving Avg: $5.38
- 200 Day Moving Avg: $5.41
- 52 Week Range: $3.28 - $7.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.44
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.16 per share
- Price / Book: 4.35
Profitability:- EBIDTA: ($51,980,000.00)
- Return on Equity: -101.62%
- Return on Assets: -71.11%
Debt:- Debt-to-Equity Ratio: 0.37%
- Current Ratio: 4.97%
- Quick Ratio: 4.97%
Misc:- Average Volume: 255,490 shs.
- Beta: 2.24
- Short Ratio: 18.88
Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its earnings results on Thursday, May, 4th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.06. View Genocea Biosciences' Earnings History.
Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?
4 brokerages have issued 1-year target prices for Genocea Biosciences' shares. Their predictions range from $12.00 to $40.00. On average, they anticipate Genocea Biosciences' share price to reach $21.00 in the next twelve months. View Analyst Ratings for Genocea Biosciences.
What are analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (7/17/2017)
- 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Nabriva Therapeutics AG (NBRV), Codexis (CDXS), Voyager Therapeutics (VYGR), Corvus Pharmaceuticals (CRVS), Zynerba Pharmaceuticals (ZYNE), Horizon Discovery Group PLC (HZD), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK), Arbutus Biopharma Corporation (ABUS), Compugen (CGEN), Merrimack Pharmaceuticals (MACK), Novelion Therapeutics (NVLN), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Chromadex Corp (CDXC), OncoMed Pharmaceuticals (OMED), Matinas BioPharma Holdings (MTNB) and Oramed Pharmaceuticals (ORMP).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Katrine S. Bosley, Chairman of the Board
- William D. Clark, President, Chief Executive Officer, Director
- Jonathan M. Poole, Chief Financial Officer
- John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
- Jessica Baker Flechtner Ph.D., Chief Scientific Officer
- Seth V. Hetherington M.D., Chief Medical Officer
- Eric S. Hoffman Ph.D., Chief Business Officer
- Ronald Harold Wilfred Cooper, Director
- George Siber M.D., Director
- Kenneth M. Bate, Independent Director
How do I buy Genocea Biosciences stock?
Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of Genocea Biosciences stock can currently be purchased for approximately $5.05.
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $21.00 (315.84% upside) |
Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 2/17/2017 | Needham & Company LLC | Downgrade | Buy -> Hold | | N/A |  |
| 1/23/2017 | FBR & Co | Reiterated Rating | Outperform | | N/A | |
| 12/14/2016 | Cowen and Company | Set Price Target | Buy | $40.00 | N/A | |
| 9/29/2016 | Piper Jaffray Companies | Lower Price Target | Overweight | $9.00 -> $12.00 | N/A | |
| 4/1/2016 | Stifel Nicolaus | Boost Price Target | Buy | $11.00 -> $13.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Genocea Biosciences (NASDAQ:GNCA)Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | 3/31/2017 | ($0.54) | ($0.48) | | | View | Listen | |
| 2/16/2017 | Q416 | ($0.45) | ($0.56) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.44) | ($0.45) | | | View | N/A | |
| 8/4/2016 | Q216 | ($0.44) | ($0.39) | | | View | N/A | |
| 5/5/2016 | Q116 | ($0.42) | ($0.35) | | $0.24 million | View | N/A | |
| 2/11/2016 | Q415 | ($0.40) | ($0.37) | | $0.22 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.43) | ($0.37) | | $0.21 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.51) | ($0.43) | | $0.12 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.57) | ($0.64) | | $0.12 million | View | Listen | |
| 2/12/2015 | Q414 | ($0.53) | ($0.66) | | $0.31 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.43) | ($0.53) | | | View | N/A | |
| 8/6/2014 | Q2 | ($0.42) | ($0.41) | | | View | N/A | |
| 5/6/2014 | Q114 | ($0.60) | ($0.76) | $0.26 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)Current Year EPS Consensus Estimate: $-1.87 EPS
Next Year EPS Consensus Estimate: $-2.07 EPS
Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 54.22%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/8/2016 | Eric S. Hoffman | Insider | Buy | 7,000 | $3.49 | $24,430.00 | |
| 11/7/2016 | Jonathan Poole | CFO | Buy | 7,000 | $3.34 | $23,380.00 | |
| 11/7/2016 | William D. Clark | Insider | Buy | 2,800 | $3.49 | $9,772.00 | |
| 5/9/2016 | Jonathan Poole | CFO | Buy | 4,000 | $3.88 | $15,520.00 | |
| 12/16/2015 | William D Clark | CEO | Buy | 3,800 | $6.45 | $24,510.00 | |
| 9/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $11.35 | $25,299.15 | |
| 6/19/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 30,004 | $13.04 | $391,252.16 | |
| 6/17/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 10,618 | $13.01 | $138,140.18 | |
| 6/16/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 46,000 | $13.24 | $609,040.00 | |
| 6/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.52 | $23,449.08 | |
| 5/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.21 | $22,758.09 | |
| 4/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,283 | $11.77 | $26,870.91 | |
| 3/17/2015 | Stephen J Hoffman | Director | Buy | 700,000 | $8.25 | $5,775,000.00 | |
| 2/2/2015 | Jessica Baker Flechtner | VP | Sell | 4,699 | $8.50 | $39,941.50 | |
| 9/12/2014 | Jessica Baker Flechtner | VP | Sell | 6,435 | $12.00 | $77,220.00 | |
| 9/11/2014 | Paul Giannasca | VP | Sell | 4,071 | $11.84 | $48,200.64 | |
| 9/10/2014 | Paul Giannasca | VP | Sell | 834 | $12.35 | $10,299.90 | |
| 9/9/2014 | Paul Giannasca | VP | Sell | 2,455 | $12.43 | $30,515.65 | |
| 9/8/2014 | Paul Giannasca | VP | Sell | 2,970 | $12.80 | $38,016.00 | |
| 8/29/2014 | Paul Giannasca | VP | Sell | 6,760 | $12.50 | $84,500.00 | |
| 8/14/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 9,660 | $13.01 | $125,676.60 | |
| 8/12/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 63,794 | $13.28 | $847,184.32 | |
| 2/10/2014 | Plc Glaxosmithkline | Insider | Buy | 143,773 | $12.00 | $1,725,276.00 | |
| 2/10/2014 | Polaris Venture Management Co. | Major Shareholder | Buy | 232,820 | $12.00 | $2,793,840.00 | |
| 2/10/2014 | Stephen J Hoffman | Director | Buy | 250,931 | $12.00 | $3,011,172.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
| Source: |
|
| Date | Headline |
|---|
 | Genocea Biosciences, Inc. (NASDAQ:GNCA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 11:08 PM |
| Genocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - July 14 at 11:32 AM |
| Genocea Biosciences, Inc. (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM |
 | Genocea Added to Russell 3000® and Russell 2000® Indices
finance.yahoo.com - June 26 at 9:32 AM |
| Brokerages Anticipate Genocea Biosciences, Inc. (GNCA) Will Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - June 20 at 8:16 AM |
| Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 16 at 8:16 AM |
| Genocea Biosciences Inc (GNCA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - June 6 at 11:02 PM |
| Genocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 5 at 11:16 PM |
 | Genocea: Investment Update On ~$6 Biotech 'Busted IPO ... - Seeking Alpha
seekingalpha.com - June 1 at 3:28 AM |
| Genocea Biosciences Inc (GNCA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 31 at 11:24 PM |
| Genocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 31 at 12:02 AM |
| Genocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM |
| Genocea Biosciences Inc (GNCA) Short Interest Update
www.americanbankingnews.com - May 16 at 7:20 AM |
| Genocea Biosciences Inc (GNCA) Issues Earnings Results
www.americanbankingnews.com - May 8 at 4:40 PM |
| Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes
finance.yahoo.com - May 4 at 12:07 PM |
| Investor Network: Genocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:07 PM |
 | Genocea Biosciences reports 1Q loss
marketbeat.com - May 4 at 9:29 AM |
| Zacks: Brokerages Expect Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - May 2 at 12:06 AM |
| Genocea Biosciences (GNCA) Earning Somewhat Critical Media Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 8:02 AM |
| Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET
finance.yahoo.com - April 27 at 8:05 AM |
| Somewhat Positive Press Coverage Extremely Likely to Impact Genocea Biosciences (GNCA) Stock Price
www.americanbankingnews.com - April 26 at 8:44 AM |
| Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 11:05 AM |
| Genocea Biosciences (GNCA) Receives Media Impact Score of -0.22
www.americanbankingnews.com - April 20 at 8:53 AM |
| Genocea Biosciences (GNCA) Receiving Very Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 8:58 AM |
| Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes
finance.yahoo.com - April 11 at 12:15 PM |
| Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 10 at 8:30 PM |
| Genocea Biosciences (GNCA) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 10:05 AM |
| Genocea Biosciences Inc (GNCA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 30 at 12:58 PM |
| Genocea to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 11:07 AM |
 | Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher - Nasdaq
www.nasdaq.com - March 9 at 5:55 PM |
| Genocea Biosciences (GNCA) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 6:17 PM |
 | Genocea Biosciences (GNCA) Appoints Howard Mayer M.D. to ... - StreetInsider.com
www.streetinsider.com - March 7 at 11:22 AM |
| GENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
biz.yahoo.com - March 6 at 5:08 PM |
| Howard Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors
finance.yahoo.com - March 6 at 9:27 AM |
| Genocea to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 12:15 PM |
| GENOCEA BIOSCIENCES, INC. Financials
finance.yahoo.com - February 23 at 5:29 PM |
| GENOCEA BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 18 at 12:23 PM |
| Genocea Biosciences downgraded by Needham
finance.yahoo.com - February 17 at 4:04 PM |
| Q4 2016 Genocea Biosciences Inc Earnings Release - Time Not Supplied
us.rd.yahoo.com - February 16 at 5:24 PM |
 | Genocea Reports Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - February 16 at 5:24 PM |
| GENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - February 16 at 5:24 PM |
| Genocea to Host Fourth Quarter and Year End 2016 Financial Results Conference Call & Webcast on February 16, 2017
finance.yahoo.com - February 9 at 6:16 PM |
| Should You Sell Genocea Biosciences (GNCA) Before Earnings? - Nasdaq
www.nasdaq.com - February 8 at 11:06 PM |
| Should You Sell Genocea Biosciences (GNCA) Before Earnings?
finance.yahoo.com - February 7 at 6:45 PM |
| Genocea Reports Positive 6-Month Results From GEN-003 Phase 2b Trial
www.nasdaq.com - January 5 at 6:25 PM |
| Genocea Biosciences (GNCA) Announces Positive Interim Analysis of GEN-003 Phase 2b Clinical Trial
www.streetinsider.com - January 5 at 6:25 PM |
Genocea Biosciences (GNCA) Chart for Saturday, July, 22, 2017
